1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Regulation

Post-Brexit Divergence Would Harm UK Industry

BGMA Director General Warwick Smith Talks Brexit Implications

 
• By Dave Wallace

On the eve of the UK’s formal exit from the EU on 31 January, BGMA director general Warwick Smith has insisted that it is essential for the UK to stay as close as possible to the current European medicines framework following the conclusion of a transition period that is currently due to expire at the end of 2020.

Arrow_Flags_Pavement
Divergence from the European framework would harm industry and patients • Source: Shutterstock

Departing from the European regulatory framework for medicines following the UK’s exit from the EU would pose a significant risk for both the UK off-patent industry and for patient access to affordable medicines, according to Warwick Smith, director general of the British Generic Manufacturers Association and the British Biosimilars Association.

Speaking to Generics Bulletin just ahead of the UK’s formal departure from the EU, Smith noted that, for the moment, operations for generics and biosimilars players with UK interests would “carry on as normal” immediately after the formal exit date of 31 January

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.